Alam Khan, MD
Neurology · London, KYNPI 1629047162
Payments from drug & device makers
Across 750 payments — averaging $118.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- Biohaven Pharmaceuticals, Inc.$25K
- Biohaven Pharmaceutical Holding Company Ltd.$5K
- Livanova USA, Inc.$1K
- Novartis$738
- AstraZeneca$653
- plus $7K from 53 others
What the payments were for
- Speaking & faculty fees$76,70586%
- Travel & lodging$6571%
- Food & beverage$11,17913%
- Education$6781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$37,179
- QULIPTA$36,744
- NURTEC ODT$29,237
- VNS Therapy$884
- GOCOVRI$269
- ULTOMIRIS$200
- VALTOCO$119
- Nayzilam$116
How this compares
$89,219 in reported general payments places this provider in the 85th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 71 | $759,963 |
| AubagioTeriflunomide | 40 | $360,001 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 43 | $339,396 |
| NuplazidPimavanserin Tartrate | 24 | $180,568 |
| GilenyaFingolimod Hcl | 14 | $146,144 |
| AptiomEslicarbazepine Acetate | 79 | $122,683 |
| BetaseronInterferon Beta-1b | 11 | $107,281 |
| IngrezzaValbenazine Tosylate | 12 | $100,957 |
| BriviactBrivaracetam | 40 | $91,278 |
| Nurtec OdtRimegepant Sulfate | 62 | $89,199 |
| Trokendi XrTopiramate | 30 | $64,669 |
| UbrelvyUbrogepant | 48 | $61,577 |
| BotoxOnabotulinumtoxina | 36 | $48,532 |
| Dalfampridine ErDalfampridine | 133 | $45,349 |
| QuliptaAtogepant | 37 | $39,482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $486 | $428,595105 claims |
| SanofiAubagio | $19 | $360,00140 claims |
| Acadia Pharmaceuticals IncNuplazid | $118 | $180,56824 claims |
| AbbVieUbrelvy, Botox, Qulipta, Namzaric, Linzess | $49,949 | $168,271147 claims |
| NovartisGilenya | $738 | $146,14414 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $140 | $122,68379 claims |
| UCB, Inc.Briviact, Vimpat | $608 | $112,01555 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $68 | $100,95712 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr | $113 | $89,16348 claims |
| Neurelis, Inc.Valtoco | $201 | $28,10833 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16 | $21,54413 claims |
| SK Life Science, Inc.Xcopri | $55 | $15,53313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 neurology providers in Kentucky.
Other neurology in London
- James MaynardFort Thomas$12.4M
- Gregory JichaLexington$7.1M
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
- Nicole EvermanLexington$834K
- Geeta GaneshLouisville$765K
- Zabeen MahuwalaLexington$694K
- Peter HederaLouisville$422K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.